<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC2889173/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome Wide Association (GWA) Predictors Of Anti-TNFα Therapeutic Responsiveness In Pediatric Inflammatory Bowel Disease (IBD)</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889173/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Inflammatory bowel diseases"><meta name="citation_title" content="Genome Wide Association (GWA) Predictors Of Anti-TNFα Therapeutic Responsiveness In Pediatric Inflammatory Bowel Disease (IBD)"><meta name="citation_authors" content="Marla C Dubinsky, Ling Mei, Madison Friedman, Tanvi Dhere, Talin Haritunians, Hakon Hakonarson, Cecilia Kim, Joseph Glessner, Stephan R Targan, Dermot P McGovern, Kent D Taylor, Jerome I Rotter"><meta name="citation_date" content="August 2010"><meta name="citation_issue" content="8"><meta name="citation_volume" content="16"><meta name="citation_firstpage" content="1357"><meta name="citation_doi" content="10.1002/ibd.21174"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2889173/?report=abstract"><meta name="citation_pmid" content="20014019"><meta name="DC.Title" content="Genome Wide Association (GWA) Predictors Of Anti-TNFα Therapeutic Responsiveness In Pediatric Inflammatory Bowel Disease (IBD)"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Marla C Dubinsky"><meta name="DC.Contributor" content="Ling Mei"><meta name="DC.Contributor" content="Madison Friedman"><meta name="DC.Contributor" content="Tanvi Dhere"><meta name="DC.Contributor" content="Talin Haritunians"><meta name="DC.Contributor" content="Hakon Hakonarson"><meta name="DC.Contributor" content="Cecilia Kim"><meta name="DC.Contributor" content="Joseph Glessner"><meta name="DC.Contributor" content="Stephan R Targan"><meta name="DC.Contributor" content="Dermot P McGovern"><meta name="DC.Contributor" content="Kent D Taylor"><meta name="DC.Contributor" content="Jerome I Rotter"><meta name="DC.Date" content="2010 Aug"><meta name="DC.Identifier" content="10.1002/ibd.21174"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome Wide Association (GWA) Predictors Of Anti-TNFα Therapeutic Responsiveness In Pediatric Inflammatory Bowel Disease (IBD)"><meta property="og:type" content="article"><meta property="og:description" content="Inter-individual variation in response to anti-TNFα therapy may be explained by genetic variability in disease pathogenesis or mechanism of action. Recent genome wide association studies (GWAS) in IBD have increased our understanding of the genetic ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889173/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2889173/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2889173/pdf/nihms-158799.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8B3B4ADD5023F10000000003190206.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-3"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2889173%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC2889173</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Inflamm Bowel Dis</a></span>. Author manuscript; available in PMC 2011 Aug 1.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><span class="cit">Inflamm Bowel Dis. 2010 Aug; 16(8): 1357–1366. </span></div> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1002%2Fibd.21174" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1002/ibd.21174</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2889173</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS158799</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20014019">20014019</a></div></div></div></div><h1 class="content-title">Genome Wide Association (GWA) Predictors Of Anti-TNFα Therapeutic Responsiveness In Pediatric Inflammatory Bowel Disease (IBD)</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Dubinsky%20MC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430587008688" co-class="co-affbox">Marla C Dubinsky</a>,<sup>1</sup> <a href="/pubmed/?term=Mei%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430597828608" co-class="co-affbox">Ling Mei</a>,<sup>1</sup> <a href="/pubmed/?term=Friedman%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430590183456" co-class="co-affbox">Madison Friedman</a>,<sup>1</sup> <a href="/pubmed/?term=Dhere%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430597036336" co-class="co-affbox">Tanvi Dhere</a>,<sup>2</sup> <a href="/pubmed/?term=Haritunians%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430634662784" co-class="co-affbox">Talin Haritunians</a>,<sup>1</sup> <a href="/pubmed/?term=Hakonarson%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430589742640" co-class="co-affbox">Hakon Hakonarson</a>,<sup>3</sup> <a href="/pubmed/?term=Kim%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430601350784" co-class="co-affbox">Cecilia Kim</a>,<sup>3</sup> <a href="/pubmed/?term=Glessner%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430595158864" co-class="co-affbox">Joseph Glessner</a>,<sup>3</sup> <a href="/pubmed/?term=Targan%20SR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430588609040" co-class="co-affbox">Stephan R Targan</a>,<sup>1</sup> <a href="/pubmed/?term=McGovern%20DP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430591363312" co-class="co-affbox">Dermot P McGovern</a>,<sup>1</sup> <a href="/pubmed/?term=Taylor%20KD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430591285472" co-class="co-affbox">Kent D Taylor</a>,<sup>1</sup> and  <a href="/pubmed/?term=Rotter%20JI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019" class="affpopup" co-rid="_co_idm140430599712384" co-class="co-affbox">Jerome I Rotter</a><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140430587008688"><h3 class="no_margin">Marla C Dubinsky</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Dubinsky%20MC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Marla C Dubinsky</a></div></div><div id="_co_idm140430597828608"><h3 class="no_margin">Ling Mei</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Mei%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Ling Mei</a></div></div><div id="_co_idm140430590183456"><h3 class="no_margin">Madison Friedman</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Friedman%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Madison Friedman</a></div></div><div id="_co_idm140430597036336"><h3 class="no_margin">Tanvi Dhere</h3><p><sup>2</sup>Department of Medicine, Emory University, Atlanta GA</p><div>Find articles by <a href="/pubmed/?term=Dhere%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Tanvi Dhere</a></div></div><div id="_co_idm140430634662784"><h3 class="no_margin">Talin Haritunians</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Haritunians%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Talin Haritunians</a></div></div><div id="_co_idm140430589742640"><h3 class="no_margin">Hakon Hakonarson</h3><p><sup>3</sup>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia PA</p><div>Find articles by <a href="/pubmed/?term=Hakonarson%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Hakon Hakonarson</a></div></div><div id="_co_idm140430601350784"><h3 class="no_margin">Cecilia Kim</h3><p><sup>3</sup>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia PA</p><div>Find articles by <a href="/pubmed/?term=Kim%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Cecilia Kim</a></div></div><div id="_co_idm140430595158864"><h3 class="no_margin">Joseph Glessner</h3><p><sup>3</sup>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia PA</p><div>Find articles by <a href="/pubmed/?term=Glessner%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Joseph Glessner</a></div></div><div id="_co_idm140430588609040"><h3 class="no_margin">Stephan R Targan</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Targan%20SR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Stephan R Targan</a></div></div><div id="_co_idm140430591363312"><h3 class="no_margin">Dermot P McGovern</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=McGovern%20DP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Dermot P McGovern</a></div></div><div id="_co_idm140430591285472"><h3 class="no_margin">Kent D Taylor</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Taylor%20KD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Kent D Taylor</a></div></div><div id="_co_idm140430599712384"><h3 class="no_margin">Jerome I Rotter</h3><p><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</p><div>Find articles by <a href="/pubmed/?term=Rotter%20JI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20014019">Jerome I Rotter</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140430597453808_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140430597453808_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140430597453808_ai" style="display:none"><div class="fm-affl" id="A1" lang="en"><sup>1</sup>Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles CA</div><div class="fm-affl" id="A2" lang="en"><sup>2</sup>Department of Medicine, Emory University, Atlanta GA</div><div class="fm-affl" id="A3" lang="en"><sup>3</sup>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia PA</div><div id="CR1">Corresponding Author: Marla Dubinsky <a href="mailto:dev@null" data-email="gro.shsc@yksnibud.alraM" class="oemail">gro.shsc@yksnibud.alraM</a> 8635 West 3<sup>rd</sup> street, suite 1165W Los Angeles CA 90048</div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140430597453808_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>See other articles in PMC that <a href="/pmc/articles/PMC2889173/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="idm140430593093568" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140430593093568title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Background</h3><p id="P1" class="p p-first-last">Inter-individual variation in response to anti-TNFα therapy may be explained by genetic variability in disease pathogenesis or mechanism of action. Recent genome wide association studies (GWAS) in IBD have increased our understanding of the genetic susceptibility to IBD.</p></div><div id="S2" class="sec"><h3 id="S2title">Aim</h3><p id="P2" class="p p-first-last">Test associations of known IBD susceptibility loci and novel “pharmacogenetic” GWAS identified loci with primary non-response to anti-TNFα in pediatric IBD patients and develop a predictive model of primary non-response.</p></div><div id="S3" class="sec"><h3 id="S3title">Methods</h3><p id="P3" class="p p-first-last">Primary non response was defined using the HBI for CD and partial Mayo score for UC. Genotyping was performed using the Illumina Infinium platform. Chi square analysis tested associations of phenotype and genotype with primary non-response. Genetic associations were identified by testing known IBD susceptibility loci and by performing a GWAS for primary non-response. Step-wise multiple logistic regression was performed to build predictive models.</p></div><div id="S4" class="sec"><h3 id="S4title">Results</h3><p id="P4" class="p p-first-last">Non-response occurred in 22 of 94 subjects. Six known susceptibility loci were associated with primary non-response (p &lt; 0.05). Only the <em>21q22.2</em>/<em>BRWDI</em> loci remained significant in the predictive model. The most predictive model included 3 novel “pharmacogenetic” GWAS loci, the previously identified BRWD1, pANCA and a UC diagnosis (R<sup>2</sup> =0.82 and AUC = 0.98%). The relative risk of non-response increased 15 fold when number of risk factors increased from 0–2 to ≥ 3.</p></div><div id="S5" class="sec sec-last"><h3 id="S5title">Conclusion</h3><p id="P5" class="p p-first-last">The combination of phenotype and genotype is most predictive of primary non response to anti-TNFα in pediatric IBD. Defining predictors of response to anti-TNFα may allow the identification of patients who will not benefit from this class of therapy.</p></div></div></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">Introduction</h2><p id="P6" class="p p-first">Natural history observations in both early and later onset inflammatory bowel disease (IBD) have prompted the increasing use of anti-TNFα therapy for IBD patients (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862021">1</a>,<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862024">2</a>). Both the REACH (<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862033">3</a>) pediatric study and the ACCENT 1 (<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862010">4</a>) study demonstrate that infliximab is effective for the induction and maintenance response and remission in a subset of CD patients. However, the clinical trial data for all anti-TNFα therapies among adult CD patients report that 40% of patients do not respond to the induction phase (primary non-responder) and that approximately 40% of those patients who do enter the maintenance phase of the trial lose response over time (<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862046">4</a>,<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862012">5</a>,<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862028">6</a>). The pediatric REACH trial reported that close to 90% of children responded to induction, suggesting a more robust acute response to anti-TNFα therapy in children as compared to adults with CD (<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862015">1</a>,<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862054">2</a>). This primary response outcome did not, however, require children to have weaned corticosteroids to meet response criteria. This would be a more clinically robust outcome definition given that the importance of steroid sparing in the induction and maintenance phase of these therapies. Moreover, approximately 40% of children, like their adult counterparts, who entered the maintenance phase lost response and were no longer in remission and off steroids at 12 months. Primary non-response appears to be less of an issue in children than adults based on the REACH trial, but more studies are needed to assess the true incidence of primary non-response in children in a non clinical trial setting. The adult UC trials (ACT 1 and ACT 2) reported similar response rates among adult UC patients receiving infliximab as the CD trials (<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862049">7</a>). Infliximab is being used off label in children with UC and the official clinical trial for indication is currently underway. These data do suggest that children respond better to induction therapy as compared to adult CD patients, but there are many differences in the patient population and outcome measures making a comparison across trials difficult and hard to interpret. One variable that may be an important predictor of response is duration of disease at initiation of therapy, which has been suggested based on post hoc analysis in both the certolizumab and adalimumab trials conducted in the adult CD population (<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862031">5</a>,<a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862016">6</a>).</p><p id="P7" class="p p-last">However inter-individual variability in therapeutic response may be better explained by genetic variability as it relates to disease pathogenesis and mechanism of action of this class of therapies. To date, limited candidate gene association studies with anti-TNFα have been reported (<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862040">8</a>–<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862051">11</a>). Other than NOD2 (<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862042">12</a>) and IBD5 (<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_484973194">13</a>), IBD susceptibility genes identified via genome wide linkage approach or Genome Wide Association Studies (GWAS) (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862027">14</a>–<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862035">18</a>) have not been evaluated as predictors of response to anti-TNFα therapies. It would be logical as an initial step to test the known IBD susceptibility genes, under the hypothesis that anti-TNF therapy interrupts the pathophysiologic pathway these genes represent. Thus far, NOD2 was not found to be associated with therapeutic response to infliximab in these limited studies. It is conceivable that disease susceptibility genes do not influence the ultimate response to therapeutic targets given the multifactorial influences on disease and the relatively unknown functionality of these susceptibility genes. However, the GWAS approach, which identifies portions of the genome that contain genetic variants associated with specific phenotypes, may identity novel variants that contribute to therapeutic outcome i.e. discovery of genetic loci that are potentially responsible for the mechanism of altered drug response, in this case to anti-TNFα. There may also be important non genetic factors that influence or modify primary response to anti-TNFα. Among the serologic immune responses, pANCA (<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862009">11</a>,<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862053">19</a>) has been shown to be negatively associated with primary response in both CD and UC patients. PANCA is present in both CD and UC and defines a specific colitis phenotype suggesting a degree of overlap in the underlying pathway biology of these two disease subtypes (<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862007">20</a>). The results of recent genetic studies have also suggested this overlap (<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862044">21</a>). Other than duration of disease at initiation of therapy, there are likely important clinical and demographic variables that also influence therapeutic outcomes. To date, however, it remains unknown whether these are independent of genetic variability. Thus, the aims of this study were to test associations of known IBD susceptibility loci as well as novel loci identified by our pharmacogenetic GWAS with anti-TNFα response in pediatric IBD patients, and to develop a predictive model of anti-TNFα primary non-response using clinical phenotype, serologic and genetic variables.</p></div><div id="S7" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S7title">Methods</h2><div id="S8" class="sec sec-first"><h3 id="S8title">Patient Population</h3><p id="P8" class="p p-first-last">A total of 94 pediatric CD and UC patients (age at diagnosis &lt; 21 years) followed at Cedars-Sinai Medical Center (CSMC) by one clinician (MD) were enrolled in this study. All subjects must have received at least 2 doses of (weeks 0 and 2) of infliximab to be eligible. Infliximab was chosen as the first line anti-TNFα used in both CD and UC for children. This study was approved by the IRB.</p></div><div id="S9" class="sec"><h3 id="S9title">Phenotyping</h3><p id="P9" class="p p-first">All data was collected by chart review and stored in a secured database. For the purpose of this study phenotype was defined as all variables that were not genetic.</p><div id="S10" class="sec"><p></p><h4 id="S10title" class="inline">Clinical Phenotype </h4><p id="P10" class="p p-first-last">These included demographic and clinical variables: age, gender, IBD subtype (CD vs. UC), disease duration, age at diagnosis, age at initiation of infliximab, immunomodulator history, steroid history, Harvey Bradshaw Index (HBI) activity scores, Partial Mayo scores and reason for infliximab discontinuation.</p></div><div id="S11" class="sec sec-last"><p></p><h4 id="S11title" class="inline">Immune Phenotype </h4><p id="P11" class="p p-first-last">Serum was collected on all patients and analyzed at CSMC. Serum immune responses: anti-saccharomyces cereviciae antibodies (ASCA IgG and IgA), perinuclear anti-nuclear cytoplasmic antibody (pANCA), anti-flagellin (anti-CBir1), anti-outer membrane porin C (anti-OmpC) and anti-Pseudomonas fluorescens-associated sequence I2 (anti-I2) were analyzed blinded to therapeutic responsiveness by ELISA as previously described (<a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_346267550">22</a>).</p></div></div><div id="S12" class="sec"><h3 id="S12title">Genotype</h3><p id="P12" class="p p-first-last">Genotyping was performed at Children's Hospital of Philadelphia (CHOP) using the Illumina Human550 platform (n=70) and the Medical Genetics Institute at CSMC using the Illumina Human610 platform for CD samples (n=17) and HumanCNV370 platform for UC samples (n=11) (<a href="#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862030">23</a>). First, genotype data were tested for association between previously reported IBD susceptibility SNPs and anti-TNFα response. <a href="/pmc/articles/PMC2889173/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a> illustrates the 28 SNPs included in this part of the analysis and references the GWAS that first reported these associations with disease (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862045">14</a>–<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862038">18</a>). Twenty-one (<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862036">21</a>) SNPs from the Barrett CD meta-analysis GWAS (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862048">14</a>), 5 SNPS from the various UC GWAS (<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_311862541">15</a>–<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862014">17</a>) and 2 SNPs from the Kugathasan pediatric IBD GWAS (<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862047">18</a>) were analyzed. Second, the genome wide data were tested for association with anti-TNFα response (“pharmacogenetic” GWAS, see below).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p4">Known Genetic Susceptibility Loci</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430597428368" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">Chromosome/Loci of interest</th><th rowspan="1" colspan="1" valign="top" align="center">GWAS Reference<br>1 = Adult CD (<a href="#R14" rid="R14" class=" bibr popnode">14</a>)<br>2 = Adult UC (<a href="#R15" rid="R15" class=" bibr popnode">15</a>–<a href="#R17" rid="R17" class=" bibr popnode">17</a>)<br>3=Pediatric IBD (<a href="#R18" rid="R18" class=" bibr popnode">18</a>)</th><th rowspan="1" colspan="1" valign="top" align="left">Chromosome/Loci of interest</th><th rowspan="1" colspan="1" valign="top" align="center">GWAS Reference<br>1= Adult CD (<a href="#R14" rid="R14" class=" bibr popnode">14</a>)<br>2 = Adult UC (<a href="#R15" rid="R15" class=" bibr popnode">15</a>–<a href="#R17" rid="R17" class=" bibr popnode">17</a>)<br>3=Pediatric IBD (<a href="#R18" rid="R18" class=" bibr popnode">18</a>)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">1p13 / <em>PTPN22</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">6q27 / <em>CCR6</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1p36</td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="left">8q24.13 / <em>TRIB1</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1q23 / <em>ITLN1</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">9p24 / <em>JAK2</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1q24</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">9q32 / <em>TNFSF15</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1q21.2 / <em>ECM1</em></td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="left">10q21 / <em>ZNF365</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1q32.1 / <em>IL10</em></td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="left">10q24 / <em>NKX2–3</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1p31 / <em>IL23R</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">12q15</td><td rowspan="1" colspan="1" valign="top" align="center">2</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">2q37 / <em>ATG16L1</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">13q14 / <em>C13orf31</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">3p21 / MST1</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">16q12 / <em>NOD2</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5p13 / <em>PTGER4</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">17q12 / CCL2</td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5q31 / <em>IBD5</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">17q21/<em>ORMDL3</em>/<em>STAT3</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5q33 / <em>IL12b</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">
<em>20q13/ TNFRSR6B</em>
</td><td rowspan="1" colspan="1" valign="top" align="center">3</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6p21/<em>HLA-DQA1</em>/TNFα, <em>TNF</em>β</td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="left">21q22 / <em>COSLG</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6p22 / <em>CDKAL1</em></td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="left">21q22.2 / <em>BRWD1</em></td><td rowspan="1" colspan="1" valign="top" align="center">3</td></tr></tbody></table></div><div id="largeobj_idm140430597428368" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC2889173/table/T1/?report=objectonly">Open in a separate window</a></div></div></div><div id="S13" class="sec"><h3 id="S13title">Outcomes and Definitions</h3><p id="P13" class="p p-first-last">The primary outcome of this study was to identify genetic loci associated with primary non-response defined for the purpose of this study as:
</p><blockquote class="pullquote"><p id="P14"><span class="underline">CD</span>: Failure to decrease HBI ≥ 3 points (<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862025">24</a>) or increase from baseline at week 10 or 4 weeks after their last infusion if they did not receive the 3<sup>rd</sup> induction dose</p><p id="P15"><span class="underline">UC</span>: Failure to decrease ≥ 2 points or increase from baseline in the sum of stool frequency and rectal bleeding subscores of the partial Mayo score (<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862039">7</a>) and no improvement in the physician's global assessment subscore at week 10 or 4 weeks after their last infusion if they did not receive the 3<sup>rd</sup> induction dose</p></blockquote><p></p></div><div id="S14" class="sec sec-last"><h3 id="S14title">Statistical Analysis</h3><div id="S15" class="sec sec-first"><p></p><h4 id="S15title" class="inline">Univariate Analysis </h4><div id="S16" class="sec sec-first"><p></p><h5 id="S16title" class="inline">Association between clinical and demographic variables and primary non-response </h5><p id="P16" class="p p-first-last">The Chi-square test was used to check the association of primary non-response with the following categorical variables: CD vs. UC, male vs. female, serum immune response positivity, percentage of immunomodulator use at the start of infliximab and primary non-response. The Student t test was used for associations of continuous variables; age of diagnosis, disease duration and duration of immunomodulator use at the start of infliximab.</p></div><div id="S17" class="sec"><p></p><h5 id="S17title" class="inline">Association between known IBD susceptibility loci and primary non-response </h5><p id="P17" class="p p-first-last">The Chi-square test was applied to test the association between each SNP (<a href="/pmc/articles/PMC2889173/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>) and primary non-response. A dominant model based on the presence of the rare allele was assumed. Relative risk was calculated by comparing the risk of non-response in the patients with a specific genotype versus those without the genotype.</p></div><div id="S18" class="sec sec-last"><p></p><h5 id="S18title" class="inline">Pharmacogenetic genome wide association study (GWAS) </h5><ol class="enumerated" style="list-style-type:lower-alpha" id="L1"><!--
list-behavior=enumerated
prefix-word=
mark-type=lower-alpha
max-label-size=0
--><li><p id="P18">Principal components (PC) analysis (using Eigenstrat) was conducted to examine population stratification (<a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862020">25</a>). All the subjects formed one cluster with no significant outliers. We did not need to correct for population stratification during the association analysis, as the first ten PC evaluated were not significantly associated with primary non-response.</p></li><li><p id="P19">For the purpose of quality control, SNPs with a minor allele frequency (MAF) &lt;0.01, genotype failure rate &gt;0.10, HWE P value &lt;0.001 were excluded from the analysis. Allelic association between an individual SNP and primary non-response was carried out by chi-square test in PLINK (<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862050">26</a>). The first 10 SNPs with the most significant results were then retained for modeling. Following quality control, 301,742 SNPs were available in all data sets for analysis.</p></li></ol></div></div><div id="S19" class="sec sec-last"><p></p><h4 id="S19title" class="inline">Multivariate Analysis </h4><div id="S20" class="sec sec-first"><p></p><h5 id="S20title" class="inline">Predictive models of primary non-response </h5><p id="P20" class="p p-first">Models to predict non-response were built using step-wise multiple logistic regression, combining a) IBD susceptibility SNPs, b) the top 10 hits from the pharmacogenetic GWAS analysis, c) serology status and d) IBD subtypes. Since rs5975493 and rs7059861 are in high linkage disequilibrium, only rs7059861 was kept in the model. Exact logistic regression was used if the estimate from a regular regression model was not available. The significance level for a variable to enter and stay in the model was 10%. The likelihood based pseudo-R squared from the logistic regression model was used to measure the strength of association as well as the proportion of variance of the outcome accounted by the model's independent variables (<a href="#R27" rid="R27" class=" bibr popnode">27</a>). Models were built at five different levels:</p><ol class="enumerated" style="list-style-type:upper-roman" id="L2"><!--
list-behavior=enumerated
prefix-word=
mark-type=upper-roman
max-label-size=0
--><li><p id="P21">demographic variables, serology status and IBD subtype only</p></li><li><p id="P22">known IBD susceptibility SNPs only</p></li><li><p id="P23">model I and II combined</p></li><li><p id="P24">pharmacogenetic GWAS SNPs (dominant model assumed) only</p></li><li><p id="P25">model III and IV combined (final model). (known IBD susceptibility SNPs, pharmacogenetic GWAS top hits, serologic status and clinical variables)</p></li></ol></div><div id="S21" class="sec sec-last"><p></p><h5 id="S21title" class="inline">Clinical Utility Measures </h5><p id="P26" class="p p-first-last">The area under the Receiver Operating Characteristic (ROC) curve (AUC) was used as a measure of the predictive performance of the final model. The risk score was calculated based on the final model by assigning each risk phenotype or genotype as 1 point. Sensitivity [# true positives /(#of true positives + #of false negatives)], specificity [#of true negatives/(#of true negatives + #of false positives)], accuracy [(sensitivity + specificity)/2] and positive likelihood ratio test (sensitivity/(1-specificity)) for primary non response were also calculated for the final model (<a href="#R28" rid="R28" class=" bibr popnode">28</a>). All statistical analysis was conducted by SAS software v9.1 (SAS Institute; Cary, NC.).</p></div></div></div></div><div id="S22" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S22title">Results</h2><div id="S23" class="sec sec-first"><h3 id="S23title">Patient population and phenotype associations</h3><p id="P27" class="p p-first-last">Of the 94 patients evaluated, 22 patients (23 %) met the criteria of primary non-response. <a href="/pmc/articles/PMC2889173/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> illustrates the key demographic data for both responders and non responders. A diagnosis of UC (p &lt; 0.0001) and pANCA positivity (p=0.0001) were associated with primary non-response. Gender, mean age at diagnosis, disease duration at initiation of infliximab, percentage of immunomodulator use and duration of use at start of infliximab did not differ between the two groups.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p5">Phenotype Associations with Therapeutic Outcomes to Anti-TNFα</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430599641584" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">CLINICAL VARIABLE</th><th rowspan="1" colspan="1" valign="top" align="center">NON-RESPONSE</th><th rowspan="1" colspan="1" valign="top" align="center">RESPONSE</th><th rowspan="1" colspan="1" valign="top" align="center">P Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">UC vs. CD</td><td rowspan="1" colspan="1" valign="top" align="center">14:8</td><td rowspan="1" colspan="1" valign="top" align="center">6:66</td><td rowspan="1" colspan="1" valign="top" align="center">
<strong>&lt;0.0001</strong>
</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Mean age at diagnosis (years)</td><td rowspan="1" colspan="1" valign="top" align="center">10.1</td><td rowspan="1" colspan="1" valign="top" align="center">10.5</td><td rowspan="1" colspan="1" valign="top" align="center">0.71</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Gender M:F</td><td rowspan="1" colspan="1" valign="top" align="center">8:14</td><td rowspan="1" colspan="1" valign="top" align="center">40:32</td><td rowspan="1" colspan="1" valign="top" align="center">0.12</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Mean Disease duration at start of IFX (months)</td><td rowspan="1" colspan="1" valign="top" align="center">26</td><td rowspan="1" colspan="1" valign="top" align="center">25</td><td rowspan="1" colspan="1" valign="top" align="center">0.96</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">IMM use at start of IFX (%)</td><td rowspan="1" colspan="1" valign="top" align="center">79%</td><td rowspan="1" colspan="1" valign="top" align="center">92.8%</td><td rowspan="1" colspan="1" valign="top" align="center">0.1</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Mean Duration of IMM at start of IFX (months)</td><td rowspan="1" colspan="1" valign="top" align="center">12.7</td><td rowspan="1" colspan="1" valign="top" align="center">15.3</td><td rowspan="1" colspan="1" valign="top" align="center">0.57</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">pANCA +</td><td rowspan="1" colspan="1" valign="top" align="center">76.2%</td><td rowspan="1" colspan="1" valign="top" align="center">29%</td><td rowspan="1" colspan="1" valign="top" align="center">
<strong>0.0001</strong>
</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">ASCA+</td><td rowspan="1" colspan="1" valign="top" align="center">0%</td><td rowspan="1" colspan="1" valign="top" align="center">46.9%</td><td rowspan="1" colspan="1" valign="top" align="center">
<strong>0.0003</strong>
</td></tr></tbody></table></div><div id="largeobj_idm140430599641584" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/table/T2/?report=objectonly">Open in a separate window</a></div></div></div><div id="S24" class="sec"><h3 id="S24title">Genetic Associations: Univariate Analysis</h3><div id="S25" class="sec sec-first"><p></p><h4 id="S25title" class="inline">Known IBD Susceptibility Loci </h4><p id="P28" class="p p-first-last">Of the 28 previously identified genetic loci (<a href="/pmc/articles/PMC2889173/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>), 6 were found to be significantly associated with primary non-response. <a href="/pmc/articles/PMC2889173/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a> illustrates the frequency of primary non-response for the different genotypes of these 6 SNPs. Four of the 6 SNPs are from the CD meta-analysis (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862011">14</a>), 1 from the UC GWAS (<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_311862540">15</a>–<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862043">17</a>) and 1 from pediatric IBD GWAS (<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862023">18</a>). For this analysis, the dominant model of the rare allele was assumed. The common allelic variant was associated with non-response in 4 of the 6 SNPs. <a href="/pmc/articles/PMC2889173/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a> compares the reported IBD risk allele with the allele found to be associated with non-response in this study for all 6 SNPs. In only 2 of the SNPs was the disease risk allele the same as that found to be associated with non response to anti-TNFα.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2889173/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430596940208" class="figure"><a href="/pmc/articles/PMC2889173/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2889173_nihms-158799-f0001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms-158799-f0001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2889173/bin/nihms-158799-f0001.jpg"></a></div><div id="largeobj_idm140430596940208" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2889173/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p2">Genotype associations of known IBD susceptibility loci with primary non-response. The dominant rare allele model (i.e. presence of the rare allele) was assumed for the statistical analyses). The relative risk (RR) and frequency of non-response are shown for the genotypes for each locus that met p value significance in univariate analysis.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p6">Allelic Variants</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430593996672" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">SNP and Gene/Locus</th><th rowspan="1" colspan="1" valign="top" align="center">GWAS Reference<br>1 = Adult CD (<a href="#R14" rid="R14" class=" bibr popnode">14</a>)<br>2 = Adult UC (<a href="#R15" rid="R15" class=" bibr popnode">15</a>–<a href="#R17" rid="R17" class=" bibr popnode">17</a>)<br>3=Pediatric IBD (<a href="#R18" rid="R18" class=" bibr popnode">18</a></th><th rowspan="1" colspan="1" valign="top" align="center">IBD Risk Allele</th><th rowspan="1" colspan="1" valign="top" align="center">Non-Response Allele</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">rs2241880<br>2q37/ATG16L1</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">C</td><td rowspan="1" colspan="1" valign="top" align="center">T</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs2188962<br>5q31</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">T</td><td rowspan="1" colspan="1" valign="top" align="center">C</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs6908425<br>6p22/CDKAL1</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">C</td><td rowspan="1" colspan="1" valign="top" align="center">T</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs762421<br>21q22/ICOSLG</td><td rowspan="1" colspan="1" valign="top" align="center">1</td><td rowspan="1" colspan="1" valign="top" align="center">G</td><td rowspan="1" colspan="1" valign="top" align="center">A</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs2395185<br>6p21/HLA-DAQ1</td><td rowspan="1" colspan="1" valign="top" align="center">2</td><td rowspan="1" colspan="1" valign="top" align="center">G</td><td rowspan="1" colspan="1" valign="top" align="center">G</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">rs2836878<br>21q22/BRWD1</td><td rowspan="1" colspan="1" valign="top" align="center">3</td><td rowspan="1" colspan="1" valign="top" align="center">G</td><td rowspan="1" colspan="1" valign="top" align="center">G</td></tr></tbody></table></div><div id="largeobj_idm140430593996672" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/table/T3/?report=objectonly">Open in a separate window</a></div></div></div><div id="S26" class="sec sec-last"><p></p><h4 id="S26title" class="inline">Pharmacogenetic GWAS </h4><p id="P29" class="p p-first-last"><a href="/pmc/articles/PMC2889173/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a> lists the results of the chi square analyses for the pharmacogenetic GWAS. Only those SNPs with a p value &lt; 10<sup>−4</sup> are listed.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T4"><h3>Table 4</h3><!--caption a7--><div class="caption"><p id="__p7">Pharmacogenetic GWAS: p &lt; 0.0001</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430584803472" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">Chromosome</th><th rowspan="1" colspan="1" valign="top" align="left">SNP</th><th rowspan="1" colspan="1" valign="top" align="center">Position<sup>*</sup></th><th rowspan="1" colspan="1" valign="top" align="center">Gene db129<sup>*</sup>,</th><th rowspan="1" colspan="1" valign="top" align="center">Other loci<sup>**</sup>,</th><th rowspan="1" colspan="1" valign="top" align="center">OR</th><th rowspan="1" colspan="1" valign="top" align="right">P</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">13</td><td rowspan="1" colspan="1" valign="top" align="left">rs1155848</td><td rowspan="1" colspan="1" valign="top" align="center">78786477</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">RBM26</td><td rowspan="1" colspan="1" valign="top" align="center">35.73</td><td rowspan="1" colspan="1" valign="top" align="right">5.35E-07</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5</td><td rowspan="1" colspan="1" valign="top" align="left">rs1592749</td><td rowspan="1" colspan="1" valign="top" align="center">159904599</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">5.949</td><td rowspan="1" colspan="1" valign="top" align="right">1.09E-06</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs765132</td><td rowspan="1" colspan="1" valign="top" align="center">133150270</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">347475<br>|402425<br>|644403</td><td rowspan="1" colspan="1" valign="top" align="center">35</td><td rowspan="1" colspan="1" valign="top" align="right">1.09E-06</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs4707930</td><td rowspan="1" colspan="1" valign="top" align="center">72463040</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">6.603</td><td rowspan="1" colspan="1" valign="top" align="right">5.55E-06</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">10</td><td rowspan="1" colspan="1" valign="top" align="left">rs7905482</td><td rowspan="1" colspan="1" valign="top" align="center">81853944</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">PLAC9<br>|389988<br>642506<br>|642521<br>|642538<br>|727879</td><td rowspan="1" colspan="1" valign="top" align="center">4.875</td><td rowspan="1" colspan="1" valign="top" align="right">1.08E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">20</td><td rowspan="1" colspan="1" valign="top" align="left">rs6100556</td><td rowspan="1" colspan="1" valign="top" align="center">57701043</td><td rowspan="1" colspan="1" valign="top" align="center">PHACTR3</td><td rowspan="1" colspan="1" valign="top" align="center">PHACTR3</td><td rowspan="1" colspan="1" valign="top" align="center">4.951</td><td rowspan="1" colspan="1" valign="top" align="right">1.23E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs7059861</td><td rowspan="1" colspan="1" valign="top" align="center">133191565</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">347475<br>|402425</td><td rowspan="1" colspan="1" valign="top" align="center">8.333</td><td rowspan="1" colspan="1" valign="top" align="right">1.62E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs5975453</td><td rowspan="1" colspan="1" valign="top" align="center">133212999</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">347475<br>402425</td><td rowspan="1" colspan="1" valign="top" align="center">8.333</td><td rowspan="1" colspan="1" valign="top" align="right">1.62E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">10</td><td rowspan="1" colspan="1" valign="top" align="left">rs4077511</td><td rowspan="1" colspan="1" valign="top" align="center">5568172</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">CALML3<br>CALML5<br>100132159</td><td rowspan="1" colspan="1" valign="top" align="center">8.214</td><td rowspan="1" colspan="1" valign="top" align="right">1.74E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">2</td><td rowspan="1" colspan="1" valign="top" align="left">rs975664</td><td rowspan="1" colspan="1" valign="top" align="center">75222305</td><td rowspan="1" colspan="1" valign="top" align="center">TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">0.1667</td><td rowspan="1" colspan="1" valign="top" align="right">1.75E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">3</td><td rowspan="1" colspan="1" valign="top" align="left">rs4855535</td><td rowspan="1" colspan="1" valign="top" align="center">69017124</td><td rowspan="1" colspan="1" valign="top" align="center">FAM19A4</td><td rowspan="1" colspan="1" valign="top" align="center">FAM19A4</td><td rowspan="1" colspan="1" valign="top" align="center">5.619</td><td rowspan="1" colspan="1" valign="top" align="right">1.77E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">17</td><td rowspan="1" colspan="1" valign="top" align="left">rs4796606</td><td rowspan="1" colspan="1" valign="top" align="center">36917613</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">KRT13<br>|KRT15<br>|KRT32<br>|KRT35<br>|KRT38<br>|KRT37<br>|KRT36</td><td rowspan="1" colspan="1" valign="top" align="center">11.73</td><td rowspan="1" colspan="1" valign="top" align="right">1.98E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">8</td><td rowspan="1" colspan="1" valign="top" align="left">rs2943177</td><td rowspan="1" colspan="1" valign="top" align="center">88121513</td><td rowspan="1" colspan="1" valign="top" align="center">CNBD1</td><td rowspan="1" colspan="1" valign="top" align="center">CNBD1</td><td rowspan="1" colspan="1" valign="top" align="center">6.412</td><td rowspan="1" colspan="1" valign="top" align="right">2.06E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">8</td><td rowspan="1" colspan="1" valign="top" align="left">rs11991611</td><td rowspan="1" colspan="1" valign="top" align="center">139676572</td><td rowspan="1" colspan="1" valign="top" align="center">COL22A1</td><td rowspan="1" colspan="1" valign="top" align="center">FAM135B<br>COL22A1</td><td rowspan="1" colspan="1" valign="top" align="center">15.29</td><td rowspan="1" colspan="1" valign="top" align="right">2.12E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">10</td><td rowspan="1" colspan="1" valign="top" align="left">rs3740543</td><td rowspan="1" colspan="1" valign="top" align="center">129140065</td><td rowspan="1" colspan="1" valign="top" align="center">DOCK1</td><td rowspan="1" colspan="1" valign="top" align="center">DOCK1 | NPS</td><td rowspan="1" colspan="1" valign="top" align="center">4.932</td><td rowspan="1" colspan="1" valign="top" align="right">2.18E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">21</td><td rowspan="1" colspan="1" valign="top" align="left">rs2825673</td><td rowspan="1" colspan="1" valign="top" align="center">19888587</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">100128057</td><td rowspan="1" colspan="1" valign="top" align="center">6.438</td><td rowspan="1" colspan="1" valign="top" align="right">2.28E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1</td><td rowspan="1" colspan="1" valign="top" align="left">rs7521532</td><td rowspan="1" colspan="1" valign="top" align="center">70351206</td><td rowspan="1" colspan="1" valign="top" align="center">LRRC7</td><td rowspan="1" colspan="1" valign="top" align="center">SFRS11<br>|LRRC7</td><td rowspan="1" colspan="1" valign="top" align="center">7.143</td><td rowspan="1" colspan="1" valign="top" align="right">2.54E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">3</td><td rowspan="1" colspan="1" valign="top" align="left">rs4605505</td><td rowspan="1" colspan="1" valign="top" align="center">141323576</td><td rowspan="1" colspan="1" valign="top" align="center">CLSTN2</td><td rowspan="1" colspan="1" valign="top" align="center">CLSTN2</td><td rowspan="1" colspan="1" valign="top" align="center">7.143</td><td rowspan="1" colspan="1" valign="top" align="right">2.54E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">8</td><td rowspan="1" colspan="1" valign="top" align="left">rs7003556</td><td rowspan="1" colspan="1" valign="top" align="center">5213929</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">7.143</td><td rowspan="1" colspan="1" valign="top" align="right">2.54E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">14</td><td rowspan="1" colspan="1" valign="top" align="left">rs1243519</td><td rowspan="1" colspan="1" valign="top" align="center">94370110</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">GSC</td><td rowspan="1" colspan="1" valign="top" align="center">6</td><td rowspan="1" colspan="1" valign="top" align="right">3.06E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5</td><td rowspan="1" colspan="1" valign="top" align="left">rs2044111</td><td rowspan="1" colspan="1" valign="top" align="center">22897160</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">CDH12</td><td rowspan="1" colspan="1" valign="top" align="center">4.444</td><td rowspan="1" colspan="1" valign="top" align="right">3.54E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs2103867</td><td rowspan="1" colspan="1" valign="top" align="center">47374655</td><td rowspan="1" colspan="1" valign="top" align="center">TNFRSF21</td><td rowspan="1" colspan="1" valign="top" align="center">TNFRSF21</td><td rowspan="1" colspan="1" valign="top" align="center">12.07</td><td rowspan="1" colspan="1" valign="top" align="right">3.6E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">7</td><td rowspan="1" colspan="1" valign="top" align="left">rs17168564</td><td rowspan="1" colspan="1" valign="top" align="center">14977349</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">8.286</td><td rowspan="1" colspan="1" valign="top" align="right">3.68E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs10485363</td><td rowspan="1" colspan="1" valign="top" align="center">13245751</td><td rowspan="1" colspan="1" valign="top" align="center">PHACTR1</td><td rowspan="1" colspan="1" valign="top" align="center">PHACTR1</td><td rowspan="1" colspan="1" valign="top" align="center">5.182</td><td rowspan="1" colspan="1" valign="top" align="right">3.87E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5</td><td rowspan="1" colspan="1" valign="top" align="left">rs7726515</td><td rowspan="1" colspan="1" valign="top" align="center">129736249</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">5.187</td><td rowspan="1" colspan="1" valign="top" align="right">4E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">11</td><td rowspan="1" colspan="1" valign="top" align="left">rs835780</td><td rowspan="1" colspan="1" valign="top" align="center">44816947</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">TSPAN18</td><td rowspan="1" colspan="1" valign="top" align="center">5.187</td><td rowspan="1" colspan="1" valign="top" align="right">4E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">11</td><td rowspan="1" colspan="1" valign="top" align="left">rs835791</td><td rowspan="1" colspan="1" valign="top" align="center">44823513</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">TSPAN18</td><td rowspan="1" colspan="1" valign="top" align="center">5.187</td><td rowspan="1" colspan="1" valign="top" align="right">4E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1</td><td rowspan="1" colspan="1" valign="top" align="left">rs3795727</td><td rowspan="1" colspan="1" valign="top" align="center">154856074</td><td rowspan="1" colspan="1" valign="top" align="center">HAPLN2</td><td rowspan="1" colspan="1" valign="top" align="center">GPATCH4<br>|HAPLN2<br>BCAN<br>IQGAP3<br>646129</td><td rowspan="1" colspan="1" valign="top" align="center">4.5</td><td rowspan="1" colspan="1" valign="top" align="right">4.1E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs6906890</td><td rowspan="1" colspan="1" valign="top" align="center">13069206</td><td rowspan="1" colspan="1" valign="top" align="center">PHACTR1</td><td rowspan="1" colspan="1" valign="top" align="center">PHACTR1</td><td rowspan="1" colspan="1" valign="top" align="center">5.899</td><td rowspan="1" colspan="1" valign="top" align="right">4.31E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">11</td><td rowspan="1" colspan="1" valign="top" align="left">rs7124825</td><td rowspan="1" colspan="1" valign="top" align="center">44812803</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">TSPAN18</td><td rowspan="1" colspan="1" valign="top" align="center">0.1263</td><td rowspan="1" colspan="1" valign="top" align="right">4.31E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">19</td><td rowspan="1" colspan="1" valign="top" align="left">rs302827</td><td rowspan="1" colspan="1" valign="top" align="center">61102034</td><td rowspan="1" colspan="1" valign="top" align="center">NLRP13</td><td rowspan="1" colspan="1" valign="top" align="center">NLRP13<br>NLRP8<br>NLRP1</td><td rowspan="1" colspan="1" valign="top" align="center">4.545</td><td rowspan="1" colspan="1" valign="top" align="right">4.45E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">12</td><td rowspan="1" colspan="1" valign="top" align="left">rs2723829</td><td rowspan="1" colspan="1" valign="top" align="center">11819364</td><td rowspan="1" colspan="1" valign="top" align="center">ETV6</td><td rowspan="1" colspan="1" valign="top" align="center">ETV6</td><td rowspan="1" colspan="1" valign="top" align="center">4.333</td><td rowspan="1" colspan="1" valign="top" align="right">4.47E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">2</td><td rowspan="1" colspan="1" valign="top" align="left">rs1372256</td><td rowspan="1" colspan="1" valign="top" align="center">141070866</td><td rowspan="1" colspan="1" valign="top" align="center">LRP1B</td><td rowspan="1" colspan="1" valign="top" align="center">LRP1B</td><td rowspan="1" colspan="1" valign="top" align="center">4.626</td><td rowspan="1" colspan="1" valign="top" align="right">4.65E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">4</td><td rowspan="1" colspan="1" valign="top" align="left">rs13138970</td><td rowspan="1" colspan="1" valign="top" align="center">155494510</td><td rowspan="1" colspan="1" valign="top" align="center">DCHS2</td><td rowspan="1" colspan="1" valign="top" align="center">DCHS2</td><td rowspan="1" colspan="1" valign="top" align="center">5.297</td><td rowspan="1" colspan="1" valign="top" align="right">4.75E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">20</td><td rowspan="1" colspan="1" valign="top" align="left">rs1205434</td><td rowspan="1" colspan="1" valign="top" align="center">36302930</td><td rowspan="1" colspan="1" valign="top" align="center">KIAA1755</td><td rowspan="1" colspan="1" valign="top" align="center">BPI | TGM2<br>KIAA1755</td><td rowspan="1" colspan="1" valign="top" align="center">0.1526</td><td rowspan="1" colspan="1" valign="top" align="right">4.75E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">13</td><td rowspan="1" colspan="1" valign="top" align="left">rs9556658</td><td rowspan="1" colspan="1" valign="top" align="center">96476252</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">OXGR1</td><td rowspan="1" colspan="1" valign="top" align="center">6.111</td><td rowspan="1" colspan="1" valign="top" align="right">4.92E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">2</td><td rowspan="1" colspan="1" valign="top" align="left">rs7588326</td><td rowspan="1" colspan="1" valign="top" align="center">75202554</td><td rowspan="1" colspan="1" valign="top" align="center">TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">0.1826</td><td rowspan="1" colspan="1" valign="top" align="right">5.07E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">2</td><td rowspan="1" colspan="1" valign="top" align="left">rs3771823</td><td rowspan="1" colspan="1" valign="top" align="center">75205456</td><td rowspan="1" colspan="1" valign="top" align="center">TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">0.1826</td><td rowspan="1" colspan="1" valign="top" align="right">5.07E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">20</td><td rowspan="1" colspan="1" valign="top" align="left">rs1555901</td><td rowspan="1" colspan="1" valign="top" align="center">20762132</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">0.1826</td><td rowspan="1" colspan="1" valign="top" align="right">5.07E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs4465121</td><td rowspan="1" colspan="1" valign="top" align="center">133249071</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">PHF6</td><td rowspan="1" colspan="1" valign="top" align="center">7</td><td rowspan="1" colspan="1" valign="top" align="right">5.26E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs12527937</td><td rowspan="1" colspan="1" valign="top" align="center">16652564</td><td rowspan="1" colspan="1" valign="top" align="center">ATXN1</td><td rowspan="1" colspan="1" valign="top" align="center">ATXN1</td><td rowspan="1" colspan="1" valign="top" align="center">5.5</td><td rowspan="1" colspan="1" valign="top" align="right">5.74E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">7</td><td rowspan="1" colspan="1" valign="top" align="left">rs10269232</td><td rowspan="1" colspan="1" valign="top" align="center">10442565</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">100128638</td><td rowspan="1" colspan="1" valign="top" align="center">6.368</td><td rowspan="1" colspan="1" valign="top" align="right">6.33E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs3757105</td><td rowspan="1" colspan="1" valign="top" align="center">73950398</td><td rowspan="1" colspan="1" valign="top" align="center">KCNQ5</td><td rowspan="1" colspan="1" valign="top" align="center">KCNQ5</td><td rowspan="1" colspan="1" valign="top" align="center">24.2</td><td rowspan="1" colspan="1" valign="top" align="right">6.51E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">18</td><td rowspan="1" colspan="1" valign="top" align="left">rs1667216</td><td rowspan="1" colspan="1" valign="top" align="center">27383929</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">DSG2 | TTR</td><td rowspan="1" colspan="1" valign="top" align="center">4.952</td><td rowspan="1" colspan="1" valign="top" align="right">6.75E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">12</td><td rowspan="1" colspan="1" valign="top" align="left">rs278917</td><td rowspan="1" colspan="1" valign="top" align="center">39666755</td><td rowspan="1" colspan="1" valign="top" align="center">CNTN1</td><td rowspan="1" colspan="1" valign="top" align="center">CNTN1</td><td rowspan="1" colspan="1" valign="top" align="center">4.172</td><td rowspan="1" colspan="1" valign="top" align="right">6.93E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs9404502</td><td rowspan="1" colspan="1" valign="top" align="center">104605814</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">100129694</td><td rowspan="1" colspan="1" valign="top" align="center">5.409</td><td rowspan="1" colspan="1" valign="top" align="right">7.01E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs5977968</td><td rowspan="1" colspan="1" valign="top" align="center">133151511</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">347475<br>402425<br>644403</td><td rowspan="1" colspan="1" valign="top" align="center">7.333</td><td rowspan="1" colspan="1" valign="top" align="right">7.03E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">1</td><td rowspan="1" colspan="1" valign="top" align="left">rs12567958</td><td rowspan="1" colspan="1" valign="top" align="center">154861280</td><td rowspan="1" colspan="1" valign="top" align="center">HAPLN2</td><td rowspan="1" colspan="1" valign="top" align="center">GPATCH4<br>HAPLN2<br>BCAN<br>IQGAP3<br>646129</td><td rowspan="1" colspan="1" valign="top" align="center">4.167</td><td rowspan="1" colspan="1" valign="top" align="right">7.03E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">8</td><td rowspan="1" colspan="1" valign="top" align="left">rs1880473</td><td rowspan="1" colspan="1" valign="top" align="center">88079222</td><td rowspan="1" colspan="1" valign="top" align="center">CNBD1</td><td rowspan="1" colspan="1" valign="top" align="center">CNBD1</td><td rowspan="1" colspan="1" valign="top" align="center">5.085</td><td rowspan="1" colspan="1" valign="top" align="right">7.09E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">4</td><td rowspan="1" colspan="1" valign="top" align="left">rs7689941</td><td rowspan="1" colspan="1" valign="top" align="center">182246739</td><td rowspan="1" colspan="1" valign="top" align="center">hCG_2025798</td><td rowspan="1" colspan="1" valign="top" align="center">728081</td><td rowspan="1" colspan="1" valign="top" align="center">4.244</td><td rowspan="1" colspan="1" valign="top" align="right">7.3E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">17</td><td rowspan="1" colspan="1" valign="top" align="left">rs12937472</td><td rowspan="1" colspan="1" valign="top" align="center">15194290</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">PMP22<br>TEKT3</td><td rowspan="1" colspan="1" valign="top" align="center">8.509</td><td rowspan="1" colspan="1" valign="top" align="right">7.5E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">5</td><td rowspan="1" colspan="1" valign="top" align="left">rs4301261</td><td rowspan="1" colspan="1" valign="top" align="center">159902033</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">5.433</td><td rowspan="1" colspan="1" valign="top" align="right">7.59E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs1264379</td><td rowspan="1" colspan="1" valign="top" align="center">132893432</td><td rowspan="1" colspan="1" valign="top" align="center">GPC3</td><td rowspan="1" colspan="1" valign="top" align="center">GPC3</td><td rowspan="1" colspan="1" valign="top" align="center">6.092</td><td rowspan="1" colspan="1" valign="top" align="right">7.59E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs6529954</td><td rowspan="1" colspan="1" valign="top" align="center">4194349</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">0.1781</td><td rowspan="1" colspan="1" valign="top" align="right">7.69E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">22</td><td rowspan="1" colspan="1" valign="top" align="left">rs3088103</td><td rowspan="1" colspan="1" valign="top" align="center">25250048</td><td rowspan="1" colspan="1" valign="top" align="center">TPST2</td><td rowspan="1" colspan="1" valign="top" align="center">CRYBA4<br>|TPST2<br>TFIP11<br>HPS4<br>644380<br>653715<br>729905<br>100128401<br>HMGB1L10</td><td rowspan="1" colspan="1" valign="top" align="center">4.308</td><td rowspan="1" colspan="1" valign="top" align="right">7.77E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">6</td><td rowspan="1" colspan="1" valign="top" align="left">rs4711716</td><td rowspan="1" colspan="1" valign="top" align="center">42375201</td><td rowspan="1" colspan="1" valign="top" align="center">TRERF1</td><td rowspan="1" colspan="1" valign="top" align="center">TRERF1<br>387535<br>653802</td><td rowspan="1" colspan="1" valign="top" align="center">8.727</td><td rowspan="1" colspan="1" valign="top" align="right">7.82E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">7</td><td rowspan="1" colspan="1" valign="top" align="left">rs10464448</td><td rowspan="1" colspan="1" valign="top" align="center">141433796</td><td rowspan="1" colspan="1" valign="top" align="center">MGAM</td><td rowspan="1" colspan="1" valign="top" align="center">MGAM</td><td rowspan="1" colspan="1" valign="top" align="center">0.134</td><td rowspan="1" colspan="1" valign="top" align="right">8.32E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">X</td><td rowspan="1" colspan="1" valign="top" align="left">rs12559781</td><td rowspan="1" colspan="1" valign="top" align="center">4225952</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">7.973</td><td rowspan="1" colspan="1" valign="top" align="right">8.49E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">7</td><td rowspan="1" colspan="1" valign="top" align="left">rs2540678</td><td rowspan="1" colspan="1" valign="top" align="center">36227249</td><td rowspan="1" colspan="1" valign="top" align="center">EEPD1</td><td rowspan="1" colspan="1" valign="top" align="center">EEPD1</td><td rowspan="1" colspan="1" valign="top" align="center">4.6</td><td rowspan="1" colspan="1" valign="top" align="right">8.54E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">4</td><td rowspan="1" colspan="1" valign="top" align="left">rs7659755</td><td rowspan="1" colspan="1" valign="top" align="center">182246126</td><td rowspan="1" colspan="1" valign="top" align="center">hCG_2025798</td><td rowspan="1" colspan="1" valign="top" align="center">728081</td><td rowspan="1" colspan="1" valign="top" align="center">4.461</td><td rowspan="1" colspan="1" valign="top" align="right">8.62E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">13</td><td rowspan="1" colspan="1" valign="top" align="left">rs770389</td><td rowspan="1" colspan="1" valign="top" align="center">50043157</td><td rowspan="1" colspan="1" valign="top" align="center">LOC730194</td><td rowspan="1" colspan="1" valign="top" align="center">730194</td><td rowspan="1" colspan="1" valign="top" align="center">5.1</td><td rowspan="1" colspan="1" valign="top" align="right">8.96E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">21</td><td rowspan="1" colspan="1" valign="top" align="left">rs2825699</td><td rowspan="1" colspan="1" valign="top" align="center">19934102</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">5.1</td><td rowspan="1" colspan="1" valign="top" align="right">8.96E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">12</td><td rowspan="1" colspan="1" valign="top" align="left">rs7309734</td><td rowspan="1" colspan="1" valign="top" align="center">39564210</td><td rowspan="1" colspan="1" valign="top" align="center">CNTN1</td><td rowspan="1" colspan="1" valign="top" align="center">CNTN1</td><td rowspan="1" colspan="1" valign="top" align="center">4.171</td><td rowspan="1" colspan="1" valign="top" align="right">9.7E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">2</td><td rowspan="1" colspan="1" valign="top" align="left">rs11903032</td><td rowspan="1" colspan="1" valign="top" align="center">3840992</td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center"></td><td rowspan="1" colspan="1" valign="top" align="center">5.469</td><td rowspan="1" colspan="1" valign="top" align="right">9.78E-05</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">8</td><td rowspan="1" colspan="1" valign="top" align="left">rs10808755</td><td rowspan="1" colspan="1" valign="top" align="center">68679235</td><td rowspan="1" colspan="1" valign="top" align="center">CPA6</td><td rowspan="1" colspan="1" valign="top" align="center">CPA6</td><td rowspan="1" colspan="1" valign="top" align="center">0.08701</td><td rowspan="1" colspan="1" valign="top" align="right">9.87E-05</td></tr></tbody></table></div><div id="largeobj_idm140430584803472" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC2889173/table/T4/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>*</sup>Defined using dbSNP Build 129</div><div id="TFN2"><sup>**</sup>Loci include genes that overlap each SNP within 100kb of 5' end and 10kb of 3' end of each gene. Numbers refer to dbGene (NCBI).</div></div></div></div></div><div id="S27" class="sec"><h3 id="S27title">Multivariate Analysis</h3><div id="S28" class="sec sec-first-last"><p></p><h4 id="S28title" class="inline">Predictive models of non-response </h4><p id="P30" class="p p-first-last">Logistic multiple regression was employed to develop models of primary non-response. Five different models were developed. Model 1 examined the significance of pANCA and IBD subtype (UC vs. CD). Both pANCA (OR 5.4; p= 0.01) and the diagnosis of UC (OR 15.0; p = 0.0001) remained significant in model I, with an R squared (R<sup>2</sup>) of 0.48. Model II (R<sup>2</sup> = 0.30) examined the 6 SNPs from the univariate analysis. Four (<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862008">4</a>) of the 6 known IBD susceptibility SNPs remained significant; rs2188962 (5q31) (OR 3.3; p =0.04), rs6908425 (6p22/CDKAL1) (OR 3.2; p = 0.04), rs2836878 (21q22/BRWD1) (OR 3.3; p = 0.05) and rs2395185 (6p21/HLA-DAQ1) (OR 4.6; p =0.01). <a href="/pmc/articles/PMC2889173/table/T5/" target="table" class="fig-table-link figpopup" rid-figpopup="T5" rid-ob="ob-T5" co-legend-rid=""><span>Table 5</span></a> shows the results of Model III which included serology, IBD subtype and known susceptibility SNPs (combining the variables of models I and II). Only 3 SNPs survived the model when combined with these other independent variables. Model IV analyzed the top 10 SNPs from our pharmacogenetic GWAS and only 4 SNPs remained significant; rs975664 (TACR1) (OR 17.6, p = 0.0006), rs4855535 (FAM19A4)(OR 8.8, p = 0.006), rs4796606 (KRT32 KRT35 KRT36 KRT13)(OR 13.4, p= 0.01) and rs765132 (OR 30.1, p= 0.03). The R squared for this particular model was 0.67. The results of our final model (V) are shown in <a href="/pmc/articles/PMC2889173/table/T6/" target="table" class="fig-table-link figpopup" rid-figpopup="T6" rid-ob="ob-T6" co-legend-rid=""><span>Table 6</span></a>. Model V (R<sup>2</sup> = 0.82, including all variables) examined the associations of pANCA, diagnosis of UC, the 6 known susceptibility SNPs and the top 10 SNPs from the pharmacogenetic GWAS. UC, pANCA, 3 SNPs from the pharmacogenetic GWAS, and rs2836878 (21q22/BRWD1), a known susceptibility SNP originally reported in the pediatric IBD GWAS (<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862034">18</a>), remained significant.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T5"><h3>Table 5</h3><!--caption a7--><div class="caption"><p id="__p8">Model III: known susceptibility SNPs and phenotype</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430596497664" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">Model</th><th rowspan="1" colspan="1" valign="top" align="center">Variable</th><th rowspan="1" colspan="1" valign="top" align="center">P value</th><th rowspan="1" colspan="1" valign="top" align="center">OR</th><th rowspan="1" colspan="1" valign="top" align="center">R squared</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">III:</td><td rowspan="1" colspan="1" valign="top" align="center">UC vs. CD</td><td rowspan="1" colspan="1" valign="top" align="center">0.0008</td><td rowspan="1" colspan="1" valign="top" align="center">14.7</td><td rowspan="1" colspan="1" valign="top" align="center">0.59</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center">pANCA pos</td><td rowspan="1" colspan="1" valign="top" align="center">0.004</td><td rowspan="1" colspan="1" valign="top" align="center">15.3</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center">rs6908425<br>6p22.3<br>CDKA1</td><td rowspan="1" colspan="1" valign="top" align="center">0.05</td><td rowspan="1" colspan="1" valign="top" align="center">4.6</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center">rs2836878<br>21q22.2<br>BRWD1</td><td rowspan="1" colspan="1" valign="top" align="center">0.02</td><td rowspan="1" colspan="1" valign="top" align="center">9.8</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left"></td><td rowspan="1" colspan="1" valign="top" align="center">rs2395185<br>6p21<br>HLA-DQA1</td><td rowspan="1" colspan="1" valign="top" align="center">0.047</td><td rowspan="1" colspan="1" valign="top" align="center">5.4</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140430596497664" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/table/T5/?report=objectonly">Open in a separate window</a></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T6"><h3>Table 6</h3><!--caption a7--><div class="caption"><p id="__p9">Model V: Final Model</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430588801936" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">Model</th><th rowspan="1" colspan="1" valign="top" align="center">Variable</th><th rowspan="1" colspan="1" valign="top" align="center">P value</th><th rowspan="1" colspan="1" valign="top" align="center">OR</th><th rowspan="1" colspan="1" valign="top" align="center">R squared</th></tr></thead><tbody><tr><td rowspan="6" colspan="1" valign="top" align="left">V:</td><td rowspan="1" colspan="1" valign="top" align="center">Diagnosis: UC vs. CD</td><td rowspan="1" colspan="1" valign="top" align="center">0.008</td><td rowspan="1" colspan="1" valign="top" align="center">28.9</td><td rowspan="1" colspan="1" valign="top" align="center">0.82</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">pANCA pos vs neg</td><td rowspan="1" colspan="1" valign="top" align="center">0.03</td><td rowspan="1" colspan="1" valign="top" align="center">15.4</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs975664<br>2p12 / TACR1</td><td rowspan="1" colspan="1" valign="top" align="center">0.01</td><td rowspan="1" colspan="1" valign="top" align="center">26.5</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center"><em>rs4855535</em><br><em>3p14</em> / FAM19A4</td><td rowspan="1" colspan="1" valign="top" align="center">0.02</td><td rowspan="1" colspan="1" valign="top" align="center">10.8</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs6100556<br>20q13 / PHACTR3</td><td rowspan="1" colspan="1" valign="top" align="center">0.02</td><td rowspan="1" colspan="1" valign="top" align="center">13.8</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs2836878<br>21q22 / BRWD1</td><td rowspan="1" colspan="1" valign="top" align="center">0.07</td><td rowspan="1" colspan="1" valign="top" align="center">8.0</td><td rowspan="1" colspan="1" valign="top" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140430588801936" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/table/T6/?report=objectonly">Open in a separate window</a></div></div></div></div><div id="S29" class="sec sec-last"><h3 id="S29title">Clinical Utility Measures</h3><p id="P31" class="p p-first">The potential clinical utility of the final model (V) was calculated. <a href="/pmc/articles/PMC2889173/table/T7/" target="table" class="fig-table-link figpopup" rid-figpopup="T7" rid-ob="ob-T7" co-legend-rid=""><span>Table 7</span></a> lists the AUC, sensitivity, specificity, accuracy and positive likelihood ratio of non response in a patient who had at least 3 of the 6 risk factors of non response based on model V. In addition, the negative likelihood ratio, i.e. the likelihood that a patient will not be a non-responder if at least 3 risk factors are absent, was calculated at 0.06.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T7"><h3>Table 7</h3><!--caption a7--><div class="caption"><p id="__p10">Clinical Utility Measures</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430601288480" class="xtable"><table frame="box" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">Model</th><th rowspan="1" colspan="1" valign="top" align="center">Variable</th><th rowspan="1" colspan="1" valign="top" align="center">AUC</th><th rowspan="1" colspan="1" valign="top" align="center">Sensitivity</th><th rowspan="1" colspan="1" valign="top" align="center">Specificity</th><th rowspan="1" colspan="1" valign="top" align="center">Accuracy</th><th rowspan="1" colspan="1" valign="top" align="center">Positive Likelihood Ratio</th></tr></thead><tbody><tr><td rowspan="6" colspan="1" valign="top" align="left">V:</td><td rowspan="1" colspan="1" valign="top" align="center">Diagnosis</td><td rowspan="6" colspan="1" valign="top" align="center">0.98</td><td rowspan="6" colspan="1" valign="top" align="center">0.95</td><td rowspan="6" colspan="1" valign="top" align="center">0.88</td><td rowspan="6" colspan="1" valign="top" align="center">0.92</td><td rowspan="6" colspan="1" valign="top" align="center">8</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">pANCA<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs975664<br><em>2p12 TACR1</em><hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs4855535<br><em>3p14</em><br>FAM19A4<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs6100556<br>20q13<br>PHACTR3<hr></td></tr><tr><td rowspan="1" colspan="1" valign="top" align="center">rs2836878<br>21q22<br>BRWD1</td></tr></tbody></table></div><div id="largeobj_idm140430601288480" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/table/T7/?report=objectonly">Open in a separate window</a></div></div><p id="P32" class="p p-last">The relative risk of non-response was calculated based on the number of risk factors (model V) carried by an individual patient. Both the frequency of non-response and the relative risk increase with increasing number of risk factors (p &lt; 0.0001) (<a href="/pmc/articles/PMC2889173/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC2889173/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430597430944" class="figure"><a href="/pmc/articles/PMC2889173/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2889173_nihms-158799-f0002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms-158799-f0002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2889173/bin/nihms-158799-f0002.jpg"></a></div><div id="largeobj_idm140430597430944" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC2889173/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p3">Relative Risk (RR) of non-response based on number of risk factors derived from Model V (the most general model). Risk of non response was compared between patients with 2 or less risk factors as compared to 3–4 markers and then as compared to at least 5 of the 6 risk factors for non-response.</p></div></div></div></div></div><div id="S30" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S30title">Discussion</h2><p id="P33" class="p p-first">Anti-TNFα is an important and effective class of therapies for the management of both adult and pediatric IBD patients. Clinical experience suggests inter-individual variation in efficacy, both induction and maintenance, and in the occurrence of side effects. There are likely multiple host factors that influence these variations such as disease and immune phenotype as well as genetic background. The ability to predict which patient would have a lower likelihood of response before treatment is initiated in order to minimize exposure to potentially ineffective therapies may be an important consideration in our IBD patients. In the current era of risk; benefit balance; this concept may be very timely.</p><p id="P34">In this study we tested the associations of known and novel genetic loci with primary response outcome and developed a predictive model of primary non response using clinical phenotype, serologic and genetic variables. Six of the 28 known susceptibility loci tested were found to be associated with primary non response in the univariate analysis. The relative risk of primary non response ranged from 2.1–2.9. When tested in the multivariate analysis, only 4 of these loci remained significant. However when combined with the novel pharmacogenetic GWAS loci, only 1 loci remained significant. This one locus was initially reported in the pediatric IBD GWAS reported by Kugathasan et al (<a href="#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862017">18</a>). The functional significance of this locus remains unknown. Of the 10 novel pharmacogenetic GWAS loci tested in our predictive model, 3 remained significant in the final model. TACR1 is a receptor for substance P a known pro-inflammatory molecule. PHACTR3 (phosphatase and actin regulator 3) is associated with the nuclear scaffold in proliferating cells. While there is little known about FAM19A4 it is thought to be structurally related to MIP1α and function as a chemokine. The pharmacogenetic GWAS identified top loci did substantially improve the strength of the prediction of non-response compared to known susceptibility loci. In addition, a diagnosis of UC and pANCA positivity was independently associated with primary non-response. <a href="/pmc/articles/PMC2889173/table/T8/" target="table" class="fig-table-link figpopup" rid-figpopup="T8" rid-ob="ob-T8" co-legend-rid=""><span>Table 8</span></a> compares the r-squared and AUC values for all 5 models. The combination of genotype, phenotype and serotype was the best predictive model of non response to anti-TNFα with an r-squared of 0.82 and an AUC of 0.98, and substantially better than the models that included only known IBD SNPs. (models II or III).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T8"><h3>Table 8</h3><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140430599420528" class="xtable"><table frame="box" rules="all" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="top" align="left">MODEL</th><th rowspan="1" colspan="1" valign="top" align="left">MODEL DESCRIPTOR</th><th rowspan="1" colspan="1" valign="top" align="left">R SQUARED</th><th rowspan="1" colspan="1" valign="top" align="left">AUC</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">1</td><td rowspan="1" colspan="1" valign="top" align="left">Diagnosis and pANCA</td><td rowspan="1" colspan="1" valign="top" align="left">0.48</td><td rowspan="1" colspan="1" valign="top" align="left">0.9</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">II</td><td rowspan="1" colspan="1" valign="top" align="left">Known Susceptibility SNPs only</td><td rowspan="1" colspan="1" valign="top" align="left">0.3</td><td rowspan="1" colspan="1" valign="top" align="left">0.8</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">III</td><td rowspan="1" colspan="1" valign="top" align="left">Diagnosis, pANCA and known susceptibility SNPs</td><td rowspan="1" colspan="1" valign="top" align="left">0.59</td><td rowspan="1" colspan="1" valign="top" align="left">0.93</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">IV</td><td rowspan="1" colspan="1" valign="top" align="left">Pharmacogenetic GWAS SNPS only</td><td rowspan="1" colspan="1" valign="top" align="left">0.67</td><td rowspan="1" colspan="1" valign="top" align="left">0.94</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">V</td><td rowspan="1" colspan="1" valign="top" align="left">Diagnosis, pANCA, known susceptibility SNPs AND pharmacogenetic GWAS SNPs</td><td rowspan="1" colspan="1" valign="top" align="left">0.82</td><td rowspan="1" colspan="1" valign="top" align="left">0.98</td></tr></tbody></table></div><div id="largeobj_idm140430599420528" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2889173/table/T8/?report=objectonly">Open in a separate window</a></div></div><p id="P35">Our findings suggest that the majority of the known IBD susceptibility loci do not appear to greatly modify or influence primary response outcomes to anti-TNFα in pediatric IBD patients. This raises the possibility that the majority of genes that are associated with risk of disease may not influence the immune pathways that should be targeted to control or modify disease activity. The results of previously reported candidate gene association studies with anti-TNFα response have not been translated into the clinic and the functional significance of the genes tested remain unknown (<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862019">8</a>–<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_484973193">13</a>). The functionality of the cytokines and/or receptor renders them of interest as it relates to therapeutic outcome. With the GWAS approach, however, no a priori assumptions need to be set, as there is not a prior focus on a particular protein or target or enzyme as it relates to drug response. This hypothesis generating approach allows us to identify genetic variants that are associated with response and non-response and thus potentially identify pathways that are responsible and may well be apparent from a functional and mechanistic perspective. In this study we have analyzed the associations with primary non-response only, as we believed this was of the greatest clinical relevance. In future studies, the genetic, immunogenic and phenotypic influences on loss of response also need to be explored in order to determine those patients who may quickly lose their initial response.</p><p id="P36">Despite our significant findings, this study was limited by its relatively small sample size and lack of replication cohort, hence it is essentially a pilot study. It should be noted that previous important genetic discoveries were made using similarly small discovery cohorts for GWAS including the original publication of TNFSF15 (n=94) (<a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862022">29</a>) as well as the genetic associations with statin induced myopathy (85 cases, 90 controls) (<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862032">30</a>) and with Kawasaki disease (119 cases, 135 controls) (<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862041">31</a>). In this study we included all pediatric IBD subjects receiving anti-TNFα therapy. Currently clinicians treat both CD and UC with anti-TNF therapy and the clinical trial data suggest similar primary non response and steroid free remission outcomes for both disease subtypes. Moreover there is genetic and serologic evidence that there is pathway biology overlap within the spectrum of CD and UC phenotype (<a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862037">20</a>,<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_223862018">21</a>). In this study we did analyze UC, CD and shared susceptibility loci and the pharmacogenetic GWAS would identify loci that are independent of disease phenotype.</p><p id="P37" class="p p-last">Defining predictors of response to anti-TNFα will assist clinicians in choosing the appropriate therapy for the appropriate IBD patient, with the goal of maximizing efficacy and minimizing toxicity. As research progresses in defining the characteristics of patients who require biologics, of equal importance will be the research as proposed herein to individualize therapy based on who will or will not respond to different classes of IBD therapeutic interventions. The development of adverse events to anti-TNF therapies such as lymphoma, and sepsis naturally induce caution in clinicians who would like the ability to appropriately select patients who are most likely to respond to these therapies.. It is important that the findings from this study be replicated in an independent cohort and also tested in adult IBD patients. We are conducting a large prospective study with predefined outcomes in an independent pediatric cohort, which, in addition to primary non-response, will also examine loss of response and sustained response as an outcome. If replicated, the novel pharmacogenetic information gained from this pilot study has the potential to improve the management of patients in the clinic with more targeted use of the existing anti-TNFα agents, Such approaches may change the way we conduct large scale clinical trials, such that only patients with a higher probability of response to specific therapies will be enrolled in an attempt to minimize exposure to ineffective therapies and thus protect patients from treatment related serious and potentially fatal adverse events. The ultimate goal of this approach is the right therapy for the right patient.</p></div><div id="S31" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S31title">Acknowledgments</h2><div class="sec"><p id="__p1">This study was supported in part by NIH/NIDDK grant P01-DK046763; Cedars-Sinai Medical Center Inflammatory Bowel/ Immunobiology Institute Research Funds; the Feintech Family Chair in IBD (SRT); the Cedars-Sinai Board of Governors' Chair in Medical Genetics (JIR); Abe and Claire Levine Chair in Pediatric IBD (MD), NCRR grant M01-RR00425 (GCRC) and DERC grant DK063491.</p></div></div><div id="idm140430596551888" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140430596551888title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN1"></p><p id="P38" class="p p-first-last">Disclosures: Marla C Dubinsky receives grant support from Centocor and UCB pharma</p><p></p></div></div><div id="idm140430590514400" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140430590514400title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="citation">Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. <span><span class="ref-journal">Gastroenterology. </span>2006;<span class="ref-vol">130</span>:650–656.</span> [<a href="/pubmed/16530505" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Predictors+of+Crohn's+disease&amp;author=L+Beaugerie&amp;author=P+Seksik&amp;author=I+Nion-Larmurier&amp;author=JP+Gendre&amp;author=J+Cosnes&amp;volume=130&amp;publication_year=2006&amp;pages=650-656&amp;pmid=16530505&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="citation">Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1114–22.</span> [<a href="/pubmed/18725221" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Definition+of+phenotypic+characteristics+of+childhood-onset+inflammatory+bowel+disease&amp;author=J+Van+Limbergen&amp;author=RK+Russell&amp;author=HE+Drummond&amp;author=MC+Aldhous&amp;author=NK+Round&amp;volume=135&amp;publication_year=2008&amp;pages=1114-22&amp;pmid=18725221&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="citation">Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. <span><span class="ref-journal">Gastroenterology. </span>2007;<span class="ref-vol">132</span>:863–73.</span> [<a href="/pubmed/17324398" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Induction+and+maintenance+infliximab+therapy+for+the+treatment+of+moderate-to-severe+Crohn's+disease+in+children&amp;author=J+Hyams&amp;author=W+Crandall&amp;author=S+Kugathasan&amp;author=A+Griffiths&amp;author=A+Olson&amp;volume=132&amp;publication_year=2007&amp;pages=863-73&amp;pmid=17324398&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="citation">Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group  Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. <span><span class="ref-journal">Lancet. </span>2002;<span class="ref-vol">359</span>:1541–1549.</span> [<a href="/pubmed/12047962" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Maintenance+infliximab+for+Crohn's+disease:+the+ACCENT+I+randomized+trial&amp;author=SB+Hanauer&amp;author=BG+Feagan&amp;author=GR+Lichtenstein&amp;author=LF+Mayer&amp;author=S+Schreiber&amp;volume=359&amp;publication_year=2002&amp;pages=1541-1549&amp;pmid=12047962&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="citation">Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. <span><span class="ref-journal">Gastroenterology. </span>2007;<span class="ref-vol">132</span>:52–65.</span> [<a href="/pubmed/17241859" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Adalimumab+for+maintenance+of+clinical+response+and+remission+in+patients+with+Crohn's+disease:+the+CHARM+trial&amp;author=JF+Colombel&amp;author=WJ+Sandborn&amp;author=P+Rutgeerts&amp;author=R+Enns&amp;author=SB+Hanauer&amp;volume=132&amp;publication_year=2007&amp;pages=52-65&amp;pmid=17241859&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="citation">Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators  Maintenance therapy with certolizumab pegol for Crohn's disease. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">357</span>:239–250.</span> [<a href="/pubmed/17634459" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Maintenance+therapy+with+certolizumab+pegol+for+Crohn's+disease&amp;author=S+Schreiber&amp;author=M+Khaliq-Kareemi&amp;author=IC+Lawrance&amp;author=OO+Thomsen&amp;author=SB+Hanauer&amp;volume=357&amp;publication_year=2007&amp;pages=239-250&amp;pmid=17634459&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="citation">Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. <span><span class="ref-journal">New England Journal of Medicine. </span>2005;<span class="ref-vol">353</span>:2462–76.</span> [<a href="/pubmed/16339095" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=New+England+Journal+of+Medicine&amp;title=Infliximab+for+induction+and+maintenance+therapy+for+ulcerative+colitis&amp;author=P+Rutgeerts&amp;author=WJ+Sandborn&amp;author=BG+Feagan&amp;author=W+Reinisch&amp;author=A+Olson&amp;volume=353&amp;publication_year=2005&amp;pages=2462-76&amp;pmid=16339095&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="citation">Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P. Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. <span><span class="ref-journal">Aliment. Pharmacol. Ther. </span>2004;<span class="ref-vol">20</span>:303–310.</span> [<a href="/pubmed/15274667" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Aliment.+Pharmacol.+Ther&amp;title=Tumour+necrosis+factor-a+receptor+1+and+2+polymorphisms+in+inflammatory+bowel+disease+and+their+association+with+response+to+infliximab&amp;author=M+Pierik&amp;author=S+Vermeire&amp;author=KV+Steen&amp;author=S+Joossens&amp;author=G+Claessens&amp;volume=20&amp;publication_year=2004&amp;pages=303-310&amp;pmid=15274667&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="citation">Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR, Schreiber S. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. <span><span class="ref-journal">Pharmacogenomics. </span>2002;<span class="ref-vol">J. 2</span>:127–136.</span> [<a href="/pubmed/12049175" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics&amp;title=Pharmacogenetic+investigation+of+the+TNF/TNF-receptor+system+in+patients+with+chronic+active+Crohn's+disease+treated+with+infliximab&amp;author=S+Mascheretti&amp;author=J+Hampe&amp;author=T+Kuhbacher&amp;author=H+Herfarth&amp;author=M+Krawczak&amp;volume=J.+2&amp;publication_year=2002&amp;pages=127-136&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="citation">Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with_308 TNF gene polymorphism. <span><span class="ref-journal">Scand. J. Gastroenterol. </span>2002;<span class="ref-vol">37</span>:818–824.</span> [<a href="/pubmed/12190096" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Scand.+J.+Gastroenterol&amp;title=A+positive+response+to+infliximab+in+Crohn+disease:+association+with+a+higher+systemic+inflammation+before+treatment+but+not+with_308+TNF+gene+polymorphism&amp;author=E+Louis&amp;author=S+Vermeire&amp;author=P+Rutgeerts&amp;author=M+De+Vos&amp;author=A+Van+Gossum&amp;volume=37&amp;publication_year=2002&amp;pages=818-824&amp;pmid=12190096&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="citation">Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. LTa 1–1-1–1 haplotype is associated with negative response in Crohn's disease ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. <span><span class="ref-journal">Gastroenterology. </span>2001;<span class="ref-vol">120</span>:1347–1355.</span> [<a href="/pubmed/11313304" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=LTa+1–1-1–1+haplotype+is+associated+with+negative+response+in+Crohn's+disease+ANCA+pattern+and+LTA+haplotype+relationship+to+clinical+responses+to+anti-TNF+antibody+treatment+in+Crohn's+disease&amp;author=KD+Taylor&amp;author=SE+Plevy&amp;author=H+Yang&amp;author=CJ+Landers&amp;author=MJ+Barry&amp;volume=120&amp;publication_year=2001&amp;pages=1347-1355&amp;pmid=11313304&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="citation">Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP. NOD2/CARD15 does not influence response to infliximabin Crohn's disease. <span><span class="ref-journal">Gastroenterology. </span>2002;<span class="ref-vol">123</span>:106–111.</span> [<a href="/pubmed/12105838" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=NOD2/CARD15+does+not+influence+response+to+infliximabin+Crohn's+disease&amp;author=S+Vermeire&amp;author=E+Louis&amp;author=P+Rutgeerts&amp;author=M+De+Vos&amp;author=A+Van+Gossum&amp;volume=123&amp;publication_year=2002&amp;pages=106-111&amp;pmid=12105838&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="citation">Urcelay E, Mendoza JL, Martinez A, Fernandez L, Taxonera C, Diaz-Rubio M, de la Concha EG. IBD 5 (5q31) TT is associated with negative response in Crohn's disease. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. <span><span class="ref-journal">World J. Gastroenterol. </span>2005;<span class="ref-vol">11</span>:1187–1192.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4250711/">PMC free article</a>]</span> [<a href="/pubmed/15754402" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=World+J.+Gastroenterol&amp;title=IBD+5+(5q31)+TT+is+associated+with+negative+response+in+Crohn's+disease.+IBD5+polymorphisms+in+inflammatory+bowel+disease:+association+with+response+to+infliximab&amp;author=E+Urcelay&amp;author=JL+Mendoza&amp;author=A+Martinez&amp;author=L+Fernandez&amp;author=C+Taxonera&amp;volume=11&amp;publication_year=2005&amp;pages=1187-1192&amp;pmid=15754402&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="citation">Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Belgian-French IBD Consortium. Wellcome Trust Case Control Consortium. Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. <span><span class="ref-journal">Nat Genet. </span>2008;<span class="ref-vol">40</span>:955–62.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2574810/">PMC free article</a>]</span> [<a href="/pubmed/18587394" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Genome-wide+association+defines+more+than+30+distinct+susceptibility+loci+for+Crohn's+disease&amp;author=JC+Barrett&amp;author=S+Hansoul&amp;author=DL+Nicolae&amp;author=JH+Cho&amp;author=RH+Duerr&amp;volume=40&amp;publication_year=2008&amp;pages=955-62&amp;pmid=18587394&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="citation">Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Maria Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, the IBSEN study group. Mathew CG. Schreiber Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. <span><span class="ref-journal">Nat Genetics. </span>2008;<span class="ref-vol">40</span>:710–712.</span> [<a href="/pubmed/18836448" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genetics&amp;title=Schreiber+Sequence+variants+in+IL10,+ARPC2+and+multiple+other+loci+contribute+to+ulcerative+colitis+susceptibility&amp;author=A+Franke&amp;author=T+Balschun&amp;author=TH+Karlsen&amp;author=J+Sventoraityte&amp;author=S+Nikolaus&amp;volume=40&amp;publication_year=2008&amp;pages=710-712&amp;pmid=18438406&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="citation">Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, Onnie CM, Hanson CE, Blaszczyk K, Inouye M, Ewels P, Ravindrarajah R, Keniry A, Hunt S, Carter M, Watkins N, Ouwehand W, Lewis CM, Cardon L, Welcome Trust Case Control Consortium. Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC, Deloukas P, Mathew CG, Parkes M, Satsangi J. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. <span><span class="ref-journal">Nat. Genet. </span>2008;<span class="ref-vol">40</span>:710–712.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2719289/">PMC free article</a>]</span> [<a href="/pubmed/18438406" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Genet&amp;title=Genetic+determinants+of+ulcerative+colitis+include+the+ECM1+locus+and+five+loci+implicated+in+Crohn's+disease&amp;author=SA+Fisher&amp;author=M+Tremelling&amp;author=CA+Anderson&amp;author=R+Gwilliam&amp;author=S+Bumpstead&amp;volume=40&amp;publication_year=2008&amp;pages=710-712&amp;pmid=18438406&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="citation">Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, Achkar JP, Goyette P, Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, Bossa F, Griffiths AM, Ippoliti AF, Lahaie RG, Latiano A, Pare P, Proctor DD, Regueiro MD, Steinhart AH, Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, Roeder K, Duerr RH. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. <span><span class="ref-journal">Nat Genetics. </span>2009;<span class="ref-vol">41</span>(2):216–20.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2652837/">PMC free article</a>]</span> [<a href="/pubmed/19122664" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genetics&amp;title=Ulcerative+colitis-risk+loci+on+chromosomes+1p36+and+12q15+found+by+genome-wide+association+study&amp;author=MS+Silverberg&amp;author=JH+Cho&amp;author=JD+Rioux&amp;author=DP+McGovern&amp;author=J+Wu&amp;volume=41&amp;issue=2&amp;publication_year=2009&amp;pages=216-20&amp;pmid=19122664&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="citation">Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, Guthery SL, Cucchiara S, Kim CE, Frackelton EC, Annaiah K, Glessner JT, Santa E, Willson T, Eckert AW, Bonkowski E, Shaner JL, Smith RM, Otieno FG, Peterson N, Abrams DJ, Chiavacci RM, Grundmeier R, Mamula P, Tomer G, Piccoli DA, Monos DS, Annese V, Denson LA, Grant SF, Hakonarson H. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. <span><span class="ref-journal">Nat Genetics. </span><span class="ref-vol">40</span>:1211–1215.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2770437/">PMC free article</a>]</span> [<a href="/pubmed/18758464" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genetics&amp;title=Loci+on+20q13+and+21q22+are+associated+with+pediatric-onset+inflammatory+bowel+disease&amp;author=S+Kugathasan&amp;author=RN+Baldassano&amp;author=JP+Bradfield&amp;author=PM+Sleiman&amp;author=M+Imielinski&amp;volume=40&amp;pages=1211-1215&amp;pmid=18758464&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="citation">Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. <span><span class="ref-journal">Inflammatory Bowel Diseases. </span>2007;<span class="ref-vol">13</span>:123–8.</span> [<a href="/pubmed/17206703" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Inflammatory+Bowel+Diseases&amp;title=Predictors+of+early+response+to+infliximab+in+patients+with+ulcerative+colitis&amp;author=M+Ferrante&amp;author=S+Vermeire&amp;author=KH+Katsanos&amp;author=M+Noman&amp;author=G+Van+Assche&amp;volume=13&amp;publication_year=2007&amp;pages=123-8&amp;pmid=17206703&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="citation">Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. <span><span class="ref-journal">Gastroenterology. </span>1996;<span class="ref-vol">110</span>:1810–1819.</span> [<a href="/pubmed/8964407" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Perinuclear+antineutrophil+cytoplasmic+antibodies+in+patients+with+Crohn's+disease+define+a+clinical+subgroup&amp;author=EA+Vasiliauskas&amp;author=SE+Plevy&amp;author=CJ+Landers&amp;author=SW+Binder&amp;author=DM+Ferguson&amp;volume=110&amp;publication_year=1996&amp;pages=1810-1819&amp;pmid=8964407&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="citation">Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, Ouwehand W, Strachan D, McArdle W, Lewis CM, Wellcome Trust Case Control Consortium. Lobo A, Sanderson J, Jewell DP, Deloukas P, Mansfield JC, Mathew CG, Satsangi J, Parkes M. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. <span><span class="ref-journal">Gastroenterology. </span>2009;<span class="ref-vol">136</span>:523–9.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2675137/">PMC free article</a>]</span> [<a href="/pubmed/19068216" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Investigation+of+Crohn's+disease+risk+loci+in+ulcerative+colitis+further+defines+their+molecular+relationship&amp;author=CA+Anderson&amp;author=DC+Massey&amp;author=JC+Barrett&amp;author=NJ+Prescott&amp;author=M+Tremelling&amp;volume=136&amp;publication_year=2009&amp;pages=523-9&amp;pmid=19068216&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="citation">Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Oliva Hemker M, Leleiko L, Crandall W, Langton C, Landers C, Taylor KD, Targan SR, Rotter JI, Markowitz J, Hyams J, the Western Regional Pediatric IBD Research Alliance. Pediatric IBD Collaborative Research Group. the Wisconsin Pediatric IBD Alliance  Increased immune reactivity predicts aggressive complicating Crohn's disease in children. <span><span class="ref-journal">Clinical Gastroenterology and Hepatology. </span>2008;<span class="ref-vol">6</span>:1105–11.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3745777/">PMC free article</a>]</span> [<a href="/pubmed/18619921" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Gastroenterology+and+Hepatology&amp;title=Increased+immune+reactivity+predicts+aggressive+complicating+Crohn's+disease+in+children&amp;author=MC+Dubinsky&amp;author=S+Kugathasan&amp;author=L+Mei&amp;author=Y+Picornell&amp;author=J+Nebel&amp;volume=6&amp;publication_year=2008&amp;pages=1105-11&amp;pmid=18619921&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="citation">Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:549–54.</span> [<a href="/pubmed/15838508" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=A+genome-wide+scalable+SNP+genotyping+assay+using+microarray+technology&amp;author=KL+Gunderson&amp;author=FJ+Steemers&amp;author=G+Lee&amp;author=LG+Mendoza&amp;author=MS+Chee&amp;volume=37&amp;publication_year=2005&amp;pages=549-54&amp;pmid=15838508&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="citation">Harvey RF, Bradshaw JM. A simple Index of Crohn's disease activity. <span><span class="ref-journal">Lancet. </span>1980;<span class="ref-vol">1</span>:514.</span> [<a href="/pubmed/6102236" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=A+simple+Index+of+Crohn's+disease+activity&amp;author=RF+Harvey&amp;author=JM+Bradshaw&amp;volume=1&amp;publication_year=1980&amp;pages=514&amp;pmid=6102236&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="citation">Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. <span><span class="ref-journal">Nat Genet. </span>2006 Aug;<span class="ref-vol">38</span>(8):904–9.</span> [<a href="/pubmed/16862161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Principal+components+analysis+corrects+for+stratification+in+genome-wide+association+studies&amp;author=AL+Price&amp;author=NJ+Patterson&amp;author=RM+Plenge&amp;author=ME+Weinblatt&amp;author=NA+Shadick&amp;volume=38&amp;issue=8&amp;publication_year=2006&amp;pages=904-9&amp;pmid=16862161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="citation">Purcell S, Neale B, Todd-Brown K, et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:559–75.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1950838/">PMC free article</a>]</span> [<a href="/pubmed/17701901" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=PLINK:+a+tool+set+for+whole-genome+association+and+population-based+linkage+analyses&amp;author=S+Purcell&amp;author=B+Neale&amp;author=K+Todd-Brown&amp;volume=81&amp;publication_year=2007&amp;pages=559-75&amp;pmid=17701901&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="citation">Stokes ME, Davis CS, Koch GG.  <span class="ref-journal">Categorical data analysis using the SAS system.</span> 2nd edition SAS press; Cary,NC,USA: 2000.  <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Categorical+data+analysis+using+the+SAS+system&amp;author=ME+Stokes&amp;author=CS+Davis&amp;author=GG+Koch&amp;publication_year=2000&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="citation">Armitage P, Berry G, Matthews JNS.  <span class="ref-journal">Statistical Methods in Medical Research.</span> Fourth Edition Wiley-Blackwell; Malden, MA: 2002.  <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Statistical+Methods+in+Medical+Research&amp;author=P+Armitage&amp;author=G+Berry&amp;author=JNS+Matthews&amp;publication_year=2002&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="citation">Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. <span><span class="ref-journal">Human Molecular Genetics. </span>2005;<span class="ref-vol">14</span>:3499–506.</span> [<a href="/pubmed/16221758" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Human+Molecular+Genetics&amp;title=Single+nucleotide+polymorphisms+in+TNFSF15+confer+susceptibility+to+Crohn's+disease&amp;author=K+Yamazaki&amp;author=D+McGovern&amp;author=J+Ragoussis&amp;author=M+Paolucci&amp;author=H+Butler&amp;volume=14&amp;publication_year=2005&amp;pages=3499-506&amp;pmid=16221758&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="citation">SEARCH Collaborative Group. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. <span><span class="ref-journal">New England Journal of Medicine. </span>2008;<span class="ref-vol">359</span>:789–99.</span> [<a href="/pubmed/18650507" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=New+England+Journal+of+Medicine&amp;title=SLCO1B1+variants+and+statin-induced+myopathy--a+genomewide+study&amp;author=E+Link&amp;author=S+Parish&amp;author=J+Armitage&amp;author=L+Bowman&amp;author=S+Heath&amp;volume=359&amp;publication_year=2008&amp;pages=789-99&amp;pmid=18650507&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="citation">Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, Ling L, Wright VJ, Thalamuthu A, Odam M, Shimizu C, Burns JC, Levin M, Kuijpers TW, Hibberd ML, International Kawasaki Disease Genetics Consortium  A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. <span><span class="ref-journal">PLoS Genetics. </span>2009;<span class="ref-vol">5</span>:e1000319.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2607021/">PMC free article</a>]</span> [<a href="/pubmed/19132087" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genetics&amp;title=A+genome-wide+association+study+identifies+novel+and+functionally+related+susceptibility+Loci+for+Kawasaki+disease&amp;author=D+Burgner&amp;author=S+Davila&amp;author=WB+Breunis&amp;author=SB+Ng&amp;author=Y+Li&amp;volume=5&amp;publication_year=2009&amp;pages=e1000319&amp;pmid=19132087&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2889173&amp;issue-id=187954&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#idm140430593093568title">Abstract</a></li><li><a href="#S6title">Introduction</a></li><li><a href="#S7title">Methods</a></li><li><a href="#S22title">Results</a></li><li><a href="#S30title">Discussion</a></li><li><a href="#S31title">Acknowledgments</a></li><li><a href="#idm140430596551888title">Footnotes</a></li><li><a href="#idm140430590514400title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2889173/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2889173/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2889173/pdf/nihms-158799.pdf">PDF (372K)</a></li> | <li><a href="#" data-citationid="PMC2889173" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2889173%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2889173%2F&amp;text=Genome%20Wide%20Association%20(GWA)%20Predictors%20Of%20Anti-TNF%CE%B1%20Therapeutic%20Responsiveness%20In%20Pediatric%20Inflammatory%20Bowel%20Disease%20(IBD)" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2889173%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="20014019" data-aiid="2889173" data-aid="2889173" data-iid="187954" data-domainid="319" data-domain="nihpa" data-accid="PMC2889173" data-md5="fef8bfdcd4ec01c5752aeeabfb9abc30"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T04:27:25-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal104&amp;ncbi_phid=CE8B3B4ADD5023F10000000003190206&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2889173%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2889173/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>